This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Long, H. J. Search for Related Content PubMed PubMed Citation Articles by Long, H. J., III Social Bookmarking                            What's this?

Management of Metastatic Cervical Cancer: Review of the Literature

Harry J. Long, III

From the Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN

Address reprint requests to Harry J. Long, MD, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN; e-mail: long.harry{at}mayo.edu

This article reviews the English-language literature concerning chemotherapy for advanced, recurrent, or metastatic cervix carcinoma. Specifically, it reviews the available literature for active single agents, doublets, triplets, and multiple drug combination chemotherapy. Until recently, single-agent cisplatin was the drug of choice in metastatic cervix cancer. Various doublets, triplets, and quartlets have been reported to have higher objective response rates than single-agent cisplatin when compared in phase III clinical trials. Some have demonstrated improvements in progression-free survival, but only topotecan plus cisplatin has demonstrated an improvement in overall survival. This benefit is most apparent in patients who have a long disease-free interval from primary therapy and who have not received prior cisplatin as a radiosensitizer.

Author's disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Mountzios, M. A. Dimopoulos, A. Bamias, G. Vourli, H. Kalofonos, G. Aravantinos, G. Fountzilas, and C. A. Papadimitriou Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study Ann. Onc., May 20, 2009; (2009) mdn797v1. [Abstract] [Full Text] [PDF]

				S. A. Cannistra and W. P. McGuire Progress in the Management of Gynecologic Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2865 - 2866. [Full Text] [PDF]